Leah Isakov

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial

Christopher G. Wood, Pramod K. Srivastava, Ronald M. Bukowski et al. · The Lancet · 2008 · 328 citations

Urology, Surgical Oncology, Versus Observation +10

Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial

Timo Vesikari, Judith L. Kirstein, Grace Devota Go et al. · The Lancet Respiratory Medicine · 2018 · 65 citations

Vaccination, Vaccinology, Vaccine Safety +11

Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings

Eric Jonasch, Christopher G. Wood, Pheroze Tamboli et al. · British Journal of Cancer · 2008 · 56 citations · Full text

Surgical Oncology, Immunology, Clinical Findings +17

Is the FDA too conservative or too aggressive?: A Bayesian decision analysis of clinical trial design

Leah Isakov, Andrew W. Lo, Vahid Montazerhodjat · Journal of Econometrics · 2019 · 50 citations

Bayesian Decision Theory, Bayesian Statistics, Health Policy +10

A cost/benefit analysis of clinical trial designs for COVID-19 vaccine candidates

Donald A. Berry, Scott Berry, Peter Hale et al. · PLoS ONE · 2020 · 27 citations · Full text

Cost/benefit Analysis, Vaccine Hesitancy, Covid-19 +16